Vnitr Lek 2025, 71(1):8-13 | DOI: 10.36290/vnl.2025.001
Hyperuricemia and gouty arthritis
- Oddělení klinické farmakologie, FN Plzeň
Crystal-induced arthropathy is caused by the deposition of crystal deposits in joint structures. Most often in clinical practice we encounter the deposition of sodium urate crystals, which is the cause of gouty arthritis. Gouty arthritis in adulthood is one of the most common inflammatory joint disorders. Especially in the developed part of the world, where in recent years we have seen a trend towards an increase in this disease. The main risk factor for the development of gouty arthritis is hyperuricemia, i.e. a pathological increase in the level of uric acid in the blood. Gouty arthritis affects the quality of life of patients not only by significant pain, but also by a relatively close relationship to cardiovascular complications. In therapy, we use both pharmacological and non-pharmacological procedures. Control of the systemic risks of the disease must also be included in the comprehensive therapy.
Keywords: allopurinol, gouty arthritis, febuxostat, hyperuricemia.
Accepted: February 6, 2025; Published: February 18, 2025 Show citation
References
- Rychlík I, Widimský P, et al. Vnitřní lékařství II. díl. Praha: Maxdorf, 2024.
- Suchý D. Základní fakta o hyperurikemii a dně. Prakt lékaren. 2011;7(6).
- Jasvinder S, Angelo G. Gout epidemiology and comorbidities. Seminars in Arthritis and Rheumatism. 2020; 50(3):11-16.
Go to original source...
Go to PubMed...
- Schwartz SA. Disease of distinction. Explore 2. 2006(6):515-519.
Go to original source...
Go to PubMed...
- The Internet Classics Archive Aphorisms by Hippocrates. MIT. Archived from the original on 7 July 2010. Retrieved 27 July 2010.
- Pillinger MH, Rosenthal P, Abeles AM (2007). Hyperuricemia and gout: new insights into pathogenesis and treatment". Bulletin of the NYU Hospital for Joint Diseases. 2007;65(3):215-221. PMID 17922673. Archived from the original on 16 December 2008.
- Storey GD. Alfred Baring Garrod (1819-1907). Rheumatology. 2001;40(10):1189-1190.
Go to original source...
Go to PubMed...
- Němec P, et al. Revmatologie pro praxi. 2., přepracované a doplněné vydání. Praha: Grada Publsihing, 2021.
- Pavelka K, et al. Revmatologie - druhé aktualizované a rozšířené vydání. Praha: Maxdorf, 2018.
- Svobodová R. Hyperurikemie a dnavá artropatie - diagnostika a léčba. Interní Med. 2016;18(3):137-141.
Go to original source...
- Bruce M Rothschild, MD et al. Gout and pseudogout. Medscape. Jul 30, 2024.
- Bradna P. Terapie hyperurikemie a dnavé artritidy. Interní Med. 2019;21(4):212-216.
Go to original source...
- Ciferská H, Petrů L, Vachek J. Symptomatická léčba dnavé artritidy. Klin Farmakol Farm. 2016;30(2):32-37.
Go to original source...
- FitzGerald 2020 Arthritis Care Res (Hoboken). 2020 May 11;72(6):744-760.
Go to original source...
Go to PubMed...
- Richette P, Doherty M, Pascual E, et al. 2018 updated European league against rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79:31-8.
Go to original source...
Go to PubMed...
- Schumacher HR, Boice JA, Daikh DI, et al.Randomised double blind trial of etoricoxib and indomethacin in the treatment of acute gouty arthritis. BMJ. 2002;324:1482.
Go to original source...
Go to PubMed...
- Öztürk R, Atalay İB, Bulut EK, et al. Place of orthopedic surgery in gout. Eur J Rheumatol. 2019;6(4):212-215.
Go to original source...
Go to PubMed...
- Sriranganathan MK, Vinik O, Pardo Pardo J, et. al. Interventions for tophi in gout". The Cochrane Database of Systematic Reviews. 2021;8(8):CD010069.
Go to original source...
Go to PubMed...
- Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039-2052.
Go to original source...
Go to PubMed...
- John K, Botson J, John RP, et. al. Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). The Journal of Rheumatology September 2020:200460.
Go to original source...
Go to PubMed...
- Vrablík M, Borghi C, Rosolová H, et al. Diagnostika a léčba hyperurikemie v kardiovaskulární prevenci na základě patofyziologického mechanismu jejího vzniku. Expertní konsenzus českých a slovenských odborníků. 2024. Atero Review 2024;2:61-71.
- Desideri G, Borghi C. Xanthine oxidase inhibition and cardivaskular protection: Don't shoot in the dark. Eur J Intern Med. 2023 Jul;113:10-12.
Go to original source...
Go to PubMed...